Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001104659-18-049250
Filing Date
2018-08-02
Accepted
2018-08-02 17:51:52
Documents
1
Period of Report
2018-07-31

Document Format Files

Seq Description Document Type Size
1 4 a4.html 4  
1 4 a4.xml 4 5365
  Complete submission text file 0001104659-18-049250.txt   6833
Mailing Address C/O HOLLIS-EDEN PHARMACEUTICALS 4435 EASTGATE MALL STE.400 SAN DIEGO CA 92121
Business Address
BURGESS DANIEL D (Reporting) CIK: 0001239650 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-37558 | Film No.: 18989768

Mailing Address 1000 CONTINENTAL DRIVE SUITE 600 KING OF PRUSSIA PA 19406
Business Address 56 FITZWILLIAM SQUARE DUBLIN L2 2 (610) 816-6640
Nabriva Therapeutics plc (Issuer) CIK: 0001641640 (see all company filings)

EIN.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations